Acarbose: The Overlooked Longevity Drug in the ITP Data
Acarbose extended lifespan by 22% in male mice in NIA Interventions Testing Program data. It's barely known outside research circles. Here's what it is and why longevity physicians are paying attention.
The NIA Interventions Testing Program (ITP) is the gold standard for testing potential longevity interventions in mice. Rigorous, replicated across multiple sites. The ITP has tested dozens of compounds. Only a handful have shown significant lifespan extension.
Acarbose is one of them.
What acarbose does
Acarbose is an alpha-glucosidase inhibitor — it blocks the enzymes in the small intestine that break down complex carbohydrates into glucose. The result: slower glucose absorption, flatter post-meal glucose spikes, and lower peak insulin levels.
It's FDA-approved for type 2 diabetes but rarely prescribed in the US because it requires multiple daily doses (with each meal) and causes significant GI side effects when combined with typical high-carb Western diets (gas, bloating from fermentation of unabsorbed carbohydrates in the colon).
The ITP data
In ITP testing, acarbose extended median lifespan by 22% in male mice and 5% in female mice. The sex difference may relate to different baseline glucose metabolism between male and female mice.
Importantly, acarbose was most effective when started late — even when initiated in mice equivalent to 65-year-old humans. This "late life" efficacy is relatively unusual and suggests the mechanism isn't just about preventing early damage.
The mechanism hypothesis
The lifespan benefit may relate to:
1. **Glucose spike reduction**: Postprandial glucose spikes are pro-inflammatory and pro-glycation. Reducing peak levels chronically may reduce cumulative damage. 2. **Caloric restriction mimicry**: By reducing net carbohydrate absorption, acarbose produces a mild caloric restriction effect without dietary change. 3. **Gut microbiome effects**: The unabsorbed carbohydrates feed colonic bacteria, potentially producing beneficial fermentation products.
Combined with rapamycin and metformin
The ITP combination study of acarbose + rapamycin showed additive lifespan extension. This is the scientific basis for our Longevity Base stack — all three drugs together address different but complementary mechanisms of aging.
The GI side effects
The caveat: acarbose causes significant gas and bloating on high-carbohydrate diets. Patients who eat moderate-to-low carbohydrate diets tolerate it much better. Your physician will discuss whether your dietary pattern makes acarbose a reasonable fit.